PloS one · 2026
Unveiling the role of interleukin-13 in liver fibrosis of chronic hepatitis B patients: Development of a predictive model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bestari Muhammad Begawan, Wijaya Muhammad Palar, Girawan Dolvy, Agustanti Nenny, Nugraha Eka Surya
Аннотация
BACKGROUND: Developing a non-invasive model is essential for assessing liver stiffness in conditions without transient elastography, which will determine further management in chronic hepatitis B (CHB) patients.
OBJECTIVES: This study aims to evaluate the interleukin-13 role in liver fibrosis and develop a new predictive model that includes interleukin-13 and standard data such as age and platelet count.
METHODS: Patients were recruited from Hasan Sadikin General Hospital's CHB registry from October 2021 to January 2022. Patients underwent demographic data collection, complete blood count, interleukin-13, and transient elastography examinations on the same day. The platelet count variable was listed in ×109/ dL, and the interleukin-13 in pg/mL. Interleukin-13 values were categorized as positive for IL-13 with a cut-off of 5 pg/mL (ILcut5). The liver stiffness measurement was inverted to obtain a normal distribution and became inverseLSM as the model's outcome. The prediction model was formed through multiple linear regression analysis.
RESULTS AND DISCUSSION: The number of patients studied was 88. A prediction model for inverseLSM was formulated, had an R2 of 0.37, and consisted of age, platelet count, and ILcut5 with correlation coefficients of -0.221, 0.326, and -0.288, respectively. The model had no autocorrelation, multicollinearity, or significant outliers, a normal distribution appearance, and met the homoscedastic criterion. Elevated IL-13, decreased platelet count, and aging are linked to increased liver stiffness.
OBJECTIVES: This study aims to evaluate the interleukin-13 role in liver fibrosis and develop a new predictive model that includes interleukin-13 and standard data such as age and platelet count.
METHODS: Patients were recruited from Hasan Sadikin General Hospital's CHB registry from October 2021 to January 2022. Patients underwent demographic data collection, complete blood count, interleukin-13, and transient elastography examinations on the same day. The platelet count variable was listed in ×109/ dL, and the interleukin-13 in pg/mL. Interleukin-13 values were categorized as positive for IL-13 with a cut-off of 5 pg/mL (ILcut5). The liver stiffness measurement was inverted to obtain a normal distribution and became inverseLSM as the model's outcome. The prediction model was formed through multiple linear regression analysis.
RESULTS AND DISCUSSION: The number of patients studied was 88. A prediction model for inverseLSM was formulated, had an R2 of 0.37, and consisted of age, platelet count, and ILcut5 with correlation coefficients of -0.221, 0.326, and -0.288, respectively. The model had no autocorrelation, multicollinearity, or significant outliers, a normal distribution appearance, and met the homoscedastic criterion. Elevated IL-13, decreased platelet count, and aging are linked to increased liver stiffness.